The effect of pharmacological correction with vitamin D on the cytokine response in children with atopic bronchial asthma

Abstract

Aim. To study the state of the cytokine response in children with atopic bronchial asthma during pharmacological correction with vitamin D.

Methods. 63 children aged 3-17 years with atopic bronchial asthma of varying severity were examined. As a control group, 10 practically healthy children of the same age who had no history of allergic manifestations and no hereditary complications, were examined. The patients were divided into two groups matched by age: group 1 included 33 patients with mild (n=20) and moderate (n=13) bronchial asthma who received only basic anti-inflammatory therapy according to the severity of asthma; group 2 included 30 children with mild (n=18) and moderate (n=12) bronchial asthma who received basic anti-inflammatory therapy with vitamin D containing Tridrop [3 drops (1500 IU) per day for 1 month]. Patients were assessed for interleukin-2, -13 and -17 in the blood serum using a solid-phase enzyme-linked immunosorbent assay before and after treatment.

Results. The results obtained made it possible to clarify the changes in the cytokine spectrum in patients with atopic bronchial asthma in the course of the disease and the effect of pharmacological correction with vitamin D on it. The mean level of interleukin-2 in group 1 remained practically unchanged, the value of this cytokine was 2.77±1.51 pg/ml (p >0.05). In group 2, the mean interleukin-2 level increased to 5.07±1.02 pg/ml (p <0.01). The mean level of interleukin-13 in group 1 patients increased but not significantly, but in group 2 a decrease of interleukin-13 to 11.3±3.8 pg/ml (p <0.05) was registered. Interleukin-17 decreased by 2.6 times in group 2 (4.8±1.6 pg/ml, p <0.01). In group 1 there was no significant change in the level of interleukin-17, in all children it remained elevated (p >0.05).

Conclusion. Pharmacological correction with vitamin D on the background of basic anti-inflammatory therapy promotes the positive dynamics of the level of cytokines during the treatment of atopic bronchial asthma, which is related to the ability of vitamin D to regulate the function of Th2 and, as a result, to reduce the synthesis of interleukin-13 and -17, which participate in the pathogenesis of allergies and play an important protective role in bronchial asthma.

Keywords

bronchial asthma / children / vitamin D / cytokines

References

[1] Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). 2016. http://:www.ginasthma.com (access date: 14.09.2018).

[2] Averina I.A., Sergienko D.F., Duguzheva O.S., Gadzhiev R.M. Chronic lung diseases in the context of the immunogenetic effect of vitamin D. Uspekhi sovremennoy nauki. 2017; 9 (4): ­210–214. (In Russ.)

[3] Аверина И.А., Сергиенко Д.Ф., Дугужева О.С., Гаджиев Р.М. Хронические заболевания лёгких в контексте иммуногенетического влияния витамина D. Успехи соврем. науки. 2017; 9 (4): 210-214.

[4] Kurbacheva O.M., Zhestkov A.V., Nagatkin D.A. Modern view on immunopathogenesis of bronchial asthma. Rossiy­skiy allergologicheskiy zhurnal. 2016; (2): 10–14. (In Russ.)

[5] Курбачева О.М., Жестков А.В., Нагаткин Д.А. Современный взгляд на иммунопатогенез бронхиальной астмы. Рос. аллергол. ж. 2016; (2): 10-14.

[6] Wood A.M., Bassford C., Webster D. Vita­min D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax. 2011; 66 (3): 205–210. DOI: 10.1136/thx.2010.140921.

[7] Wood A.M., Bassford C., Webster D. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax. 2011; 66 (3): 205-210. DOI: 10.1136/thx.2010.140921.

[8] Vitebskaya A.V., Tikhaya M.I. Vitamin D defi­ciency and autoimmune diseases. Doktor. Ru. 2017; (4): ­45–48. (In Russ.)

[9] Витебская А.В., Тихая М.И. Дефицит витамина D и аутоиммунные заболевания. Доктор. Ру. 2017; (4): 45-48.

[10] Kupaev V.I. Bronchial asthma and vitamin D: a modern view of the problem. Astma i allergiya. 2015; (4): 5–8. (In Russ.)

[11] Купаев В.И. Бронхиальная астма и витамин D: современный взгляд на проблему. Астма и аллергия. 2015; (4): 5-8.

[12] Deryabina E.V., Kusel'man A.I. Changes of immunity in bronchial asthma and their correction. Ul'yanovskiy mediko-biologicheskiy zhurnal. 2011; (3): 71–80. (In Russ.)

[13] Дерябина Е.В., Кусельман А.И. Изменения иммунитета при бронхиальной астме и их коррекция. Ульяновский мед.-биол. ж. 2011; (3): 71-80.

[14] Shagarova S.G. The level of some cytokines in the blood serum and nasal washings in patients with bronchial asthma. Tsitokiny i vospalenie. 2010; 9 (4): ­137–138. (In Russ.)

[15] Шагарова С.Г. Содержание некоторых цитокинов в сыворотке крови и назальных смывах у больных бронхиальной астмой. Цитокины и воспаление. 2010; 9 (4): 137-138.

[16] Snopov S.A. Mechanisms of action of vitamin D on the immune system. Meditsinskaya immunologiya. 2014; 16 (6): 499–530. (In Russ.)

[17] Снопов С.А. Механизмы действия витамина D на иммунную систему. Мед. иммунол. 2014; 16 (6): 499-530. . DOI: 10.15789/1563-0625-2014-6-499-530.

[18] Smol'nikova M.V., Smirnova S.V., Il'enkova N.A, Konopleva O.S. Immunological markers of uncontrolled atopic bronchial asthma in children. Meditsinskaya immunologiya. 2017; 19 (4): 453–460. (In Russ.)

[19] Смольникова М.В., Смирнова С.В., Ильенкова Н.А, Коноплёва О.С. Иммунологические маркёры неконтролируемого течения атопической бронхиальной астмы у детей. Мед. иммунол. 2017; 19 (4): 453-460. . DOI: 10.15789/1563-0625-2017-4-453-460.

[20] Nurdina M.S., Kupaev V.I. Correlation between serum IL-17 and IL-10 level and asthma control. Vestnik sovremennoy klinicheskoy meditsiny. 2017; 10 (3): 35–38. (In Russ.)

[21] Нурдина М.С., Купаев В.И. Взаимосвязь уровня ИЛ-17, ИЛ-10 со степенью контроля бронхиальной астмы. Вестн. соврем. клин. мед. 2017; 10 (3): 35-38. DOI: 10.20969/VSKM.2017.10(3).35-38.

RIGHTS & PERMISSIONS

Allakhverdiyeva L.I., Sultanova N.G., Dzhafarova A.O.